1. Home
  2. MOLN vs EARN Comparison

MOLN vs EARN Comparison

Compare MOLN & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MOLN
  • EARN
  • Stock Information
  • Founded
  • MOLN 2004
  • EARN 2012
  • Country
  • MOLN Switzerland
  • EARN United States
  • Employees
  • MOLN N/A
  • EARN N/A
  • Industry
  • MOLN
  • EARN Real Estate Investment Trusts
  • Sector
  • MOLN
  • EARN Real Estate
  • Exchange
  • MOLN Nasdaq
  • EARN Nasdaq
  • Market Cap
  • MOLN 138.6M
  • EARN 213.3M
  • IPO Year
  • MOLN 2021
  • EARN 2013
  • Fundamental
  • Price
  • MOLN $3.59
  • EARN $5.92
  • Analyst Decision
  • MOLN
  • EARN Buy
  • Analyst Count
  • MOLN 0
  • EARN 2
  • Target Price
  • MOLN N/A
  • EARN $6.00
  • AVG Volume (30 Days)
  • MOLN 1.9K
  • EARN 230.9K
  • Earning Date
  • MOLN 08-25-2025
  • EARN 08-11-2025
  • Dividend Yield
  • MOLN N/A
  • EARN 16.16%
  • EPS Growth
  • MOLN N/A
  • EARN N/A
  • EPS
  • MOLN N/A
  • EARN N/A
  • Revenue
  • MOLN $2,525,030.00
  • EARN $35,893,000.00
  • Revenue This Year
  • MOLN N/A
  • EARN $3.21
  • Revenue Next Year
  • MOLN $866.67
  • EARN $18.63
  • P/E Ratio
  • MOLN N/A
  • EARN N/A
  • Revenue Growth
  • MOLN N/A
  • EARN 43.30
  • 52 Week Low
  • MOLN $3.36
  • EARN $4.33
  • 52 Week High
  • MOLN $12.22
  • EARN $7.20
  • Technical
  • Relative Strength Index (RSI)
  • MOLN 43.66
  • EARN 64.84
  • Support Level
  • MOLN $3.71
  • EARN $5.71
  • Resistance Level
  • MOLN $3.89
  • EARN $5.79
  • Average True Range (ATR)
  • MOLN 0.10
  • EARN 0.06
  • MACD
  • MOLN -0.01
  • EARN 0.01
  • Stochastic Oscillator
  • MOLN 20.00
  • EARN 82.14

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

Share on Social Networks: